OpenLobby.EU
Explore

Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world.

Lobbying Activity

Meeting with Olivér Várhelyi (Commissioner) and

20 Nov 2025 · Opening of new API factory

Meeting with Eero Heinäluoma (Member of the European Parliament)

19 Nov 2024 · Current Affairs

Meeting with András Tivadar Kulja (Member of the European Parliament)

10 Oct 2024 · European Healthcare

Meeting with Laurent Castillo (Member of the European Parliament) and RPP Group and Ipsen Pharma

1 Oct 2024 · Europe de la Santé

Meeting with Dolors Montserrat (Member of the European Parliament)

13 Dec 2023 · Revision of the pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and European Federation of Pharmaceutical Industries and Associations and

12 Dec 2023 · Directive on Medicinal products for human use

Meeting with Elżbieta Katarzyna Łukacijewska (Member of the European Parliament)

16 Nov 2023 · cardiovascular health

Meeting with Laura Ballarín Cereza (Member of the European Parliament, Shadow rapporteur for opinion)

27 Oct 2023 · Pharmaceutical Package (Regulation)

Meeting with István Ujhelyi (Member of the European Parliament)

26 Oct 2023 · Healthcare

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

16 Oct 2023 · Directive on Medicinal products for human use

Meeting with István Ujhelyi (Member of the European Parliament, Shadow rapporteur)

7 Sept 2023 · NCD INI report

Meeting with Tomislav Sokol (Member of the European Parliament)

30 Aug 2023 · NCDs report

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Novartis International AG and

18 Jul 2023 · Directive on Medicinal products for human use

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur) and AstraZeneca PLC

28 Feb 2023 · Medicines

Meeting with Nils Torvalds (Member of the European Parliament, Rapporteur)

25 Jan 2023 · Urban wastewater treatment

Meeting with Frédérique Ries (Member of the European Parliament) and SANOFI

13 Dec 2022 · Maintenir l'innovation pharmaceutique en Europe et l'accès des patients aux médicaments

Response to Pharmaceutical Strategy - Timely patient access to affordable medicines

6 Jul 2020

Servier is an independent French pharmaceutical Group governed by a non-profit Foundation. The Group’s governance structure ensures its sustainability, preserves its independence and allows the reinvestment of all its profits into therapeutic progress and the development of its activities. As a result, the Group invests on average 25% of its total revenue (excluding generics) every year in R&D. The Group currently employs 22,000 employees in 149 countries, of which nearly 3,000 work in R&D. Servier’s corporate growth is driven by constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Having made the strategic decision to keep a strong European foothold, its 3 research centers are in Europe (2 in France and 1 in Hungary) and it has manufacturing sites in 5 EU countries (FR, IE, ES, HU, PL) allowing it to manufacture 98% of its API production for princeps and 63 % of its shipped princeps in Europe. Servier welcomes the Commission’s work on the pharmaceutical sector and the recognition of its importance to ensure Europe’s resilience in the face of future crises. However, the pharmaceutical Roadmap does not currently contain the necessary drivers of innovation to realize its own ambition referenced in the Commissioner’s mission letter “to ensure that [the European pharmaceutical industry] remains an innovator and world leader”. To strengthen our R&D and manufacturing activities in Europe, the right conditions should be put in place to foster an ecosystem favorable to innovation. With demand for pharmaceuticals increasingly coming from outside of the EU, it is crucial that Europe enhances its competitiveness. To do so, several elements should be considered. Firstly, Europe should reinforce its manufacturing infrastructure by supporting existing production capacities and identifying strategic elements from the value chain to preserve, to avoid sanitary dependence for essential medicines. Secondly, it should develop its research capacities, creating a European health data space and delivering public-private partnership mechanisms, building on the successes of the IMI framework to encourage innovative manufacturing and accelerate the development of health solutions answering unmet needs. Thirdly, for the EU to be at the forefront of pharmaceutical innovation, a stable IP framework with world-class incentives to ensure an ecosystem favorable to the protection of innovation (patents, SPCs, pediatrics) is needed to attract investment into the development of future treatments for patients. The pandemic showed the value of step-by-step innovation and repurposing of medicines (see PCTI report attached), as well as the need to better treat chronic diseases as highly prevalent risk factors. E-health should be a priority to improve the quality of life of chronically ill patients while alleviating the burden these diseases represent for health systems. Finally, Europe needs a stable, fast, effective and globally competitive regulatory framework. We need strong collaboration with the EMA early on and throughout the development of medicines as well as regulatory approval times similar to other regions. Simplifying the administrative burden while implementing a green agenda (through e.g digital notice) would accelerate patient access and reduce medicines impact on the environment. Servier’s first priority is ensuring access to medicines to patients that rely on them. It recognizes that unequal access to new treatments is a growing concern across Europe that should be addressed without delay. Creating a High-Level Forum on Better Access to Health Innovation would enable to identify new multi-stakeholder solutions to broaden access, while reducing delays. This collaborative dialogue must be fact-based and require an analysis of the root causes and drivers of access, supply and shortage issues.
Read full response

Meeting with Stig Joergen Gren (Cabinet of Vice-President Andrus Ansip) and Sky Group and

27 Apr 2017 · Revision of the Directive on Intellectual Property Rights Enforcement